Literature DB >> 18638650

Clinical trials of treatment for personality disorders.

Joel Paris1.   

Abstract

The objective of this review is to examine clinical trials of the treatment of personality disorders (PDs). The method is a narrative review of published controlled trials of psychotherapy and pharmacotherapy. Results show that a variety of methods reduce impulsivity, with less striking results for affective instability. There is good support for well-structured methods of psychotherapy, mainly in borderline personality disorder (BPD), but evidence for the efficacy of pharmacotherapy is weak. Research on other PD categories is sparse.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638650     DOI: 10.1016/j.psc.2008.03.013

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  5 in total

Review 1.  Effectiveness of different psychotherapy approaches in the treatment of borderline personality disorder.

Authors:  Joel Paris
Journal:  Curr Psychiatry Rep       Date:  2010-02       Impact factor: 5.285

Review 2.  Management of borderline personality disorder.

Authors:  Robert S Biskin; Joel Paris
Journal:  CMAJ       Date:  2012-10-01       Impact factor: 8.262

Review 3.  Borderline personality disorder: considerations for inclusion in the Massachusetts parity list of "biologically-based" disorders.

Authors:  Mary Ellen Foti; Jeffrey Geller; Laura S Guy; John G Gunderson; Brian A Palmer; Lisa M Smith
Journal:  Psychiatr Q       Date:  2011-06

Review 4.  Borderline personality disorder in adolescents: the He-who-must-not-be-named of psychiatry.

Authors:  Marie-Pier Larrivée
Journal:  Dialogues Clin Neurosci       Date:  2013-06       Impact factor: 5.986

5.  Implementation of outpatient schema therapy for borderline personality disorder: study design.

Authors:  Marjon Nadort; Arnoud Arntz; Johannes H Smit; Josephine Giesen-Bloo; Merijn Eikelenboom; Philip Spinhoven; Thea van Asselt; Michel Wensing; Richard van Dyck
Journal:  BMC Psychiatry       Date:  2009-10-06       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.